Montelukast Repurposing Shifts Cancer Drug Strategy

Montelukast repurposing shifts cancer strategy. It arrives when immunotherapy's limits can't be ignored. But the new study published Tuesday in Nature Cancer, led by Northwestern University Feinberg School of Medicine, points directly at a receptor called CysLTR1 that tumors hijack to create a cancer-friendly microenvironment. This widely available asthma medicine reprograms neutrophils, the immune system's abundant but often wayward foot soldiers, turning them from accomplices of tumor growth into agents that restore checkpoint blockade sensitivity. For hard-to-treat tumours like triple-negative breast cancer, the paper offers both a mechanistic explanation and a therapeutic lead that leans on an already approved molecule. The science is early, but its strategic implications ripple across drug development, biomarker discovery, and oncology funding economics.

A Fresh Look at Checkpoint Resistance

Many don't benefit. For years, the dominant narrative in cancer therapy celebrated checkpoint inhibitors as a major force, so the search for ways to re-sensitize resistant tumours has become one of the field's most pressing problems. But the new research frames this resistance not as a simple failure of T-cell activation but as an active subversion of the myeloid compartment. CysLTR1, it's a receptor better known for its role in asthma and allergic inflammation, and it sits at the crossroads where tumour-derived signals redirect neutrophils into a state that shields cancer instead of attacking it. Blocking that receptor could lift an immune-suppressive barrier that blunts checkpoint antibodies. And the finding rests on a chain of causality drawn from mouse models, human blood experiments, and retrospective patient data, reinforcing that a cheap, off-patent pill might be repurposed to rewire the tumour microenvironment.

Montelukast Repurposing Meets Hard-to-Treat Cancers

Montelukast binds and blocks CysLTR1. But it's been marketed for asthma since 1998, and its safety profile, though with warnings, is extensively documented, so its availability as a generic lowers the barrier to clinical exploration. In the study, when researchers gave montelukast to mice bearing breast, colon, and melanoma-like tumours, they saw slower tumour growth, longer survival, and a reversal of immunotherapy resistance. The combination with checkpoint blockades produced what study co-author Dr. Bin Zhang called "beautiful results reflected by increased survival" across multiple tumour types. Such language is rare. It signals a conviction that the team isn't merely reporting a biological curiosity but presenting a translatable strategy. Montelukast repurposing here isn't repackaging an old drug for a marginal gain, it's anchoring a mechanism-based intervention that could expand the reach of immunotherapies into indications long written off as cold tumours.

Bin Zhang, the study’s co-author and a professor of cancer immunology at Northwestern, described the central insight in stark terms.

“You can repurpose these drugs to revive or to reprogram those neutrophils to become immune stimulatory cells that basically sensitize tumors to immunotherapy,” he told Live Science.

It's no accident. So the statement frames the repurposing effort as a deliberate attempt to commandeer an existing immune-modulatory pathway, not as a serendipitous side discovery, and it carries weight beyond the laboratory. Montelukast repurposing thus becomes a case study in rational drug repositioning, where a well-characterized target in one disease state is found to play an equally consequential role in another.

Preclinical Promise and Human Relevance

The Neutrophil Hijack

Tumours don't simply turn off immunity. They corrupt it. Cancer cells release cytokines and cysteinyl leukotrienes that push neutrophils through CysLTR1 toward a tumour-promoting program, and these misdirected cells then secrete factors that help cancer invade healthy tissue and fend off cytotoxic attacks. In human blood samples, blocking CysLTR1 with montelukast stopped neutrophils from maturing into this immunosuppressive state and reduced their capacity to silence cancer-killing immune cells. Genetic analyses further mapped the intracellular cascade, revealing signatures that appear in large cancer datasets. But patients whose tumours expressed higher levels of CysLTR1 had worse outcomes and poorer responses to checkpoint blockade, solidifying the receptor as both a prognostic marker and a candidate predictive biomarker. The circular evidence, moving from animal models to human systems and back to patient data, gives the montelukast repurposing argument a coherence that funders and clinical trial designers pay attention to.

The Biomarker Angle Changes the Calculus

Too many immuno-oncology trials founder because they enroll unselected populations and then struggle to detect a signal. The Northwestern team proposes that CysLTR1 screening could identify which patients are most likely to resist standard immunotherapy and who might benefit from the addition of montelukast. This biomarker logic transforms the repurposing story from a one-size-fits-all salvage therapy into a precision medicine play. If further validation holds, a simple diagnostic test for CysLTR1 expression could guide treatment decisions, matching a generic drug to a molecularly defined subgroup. The downstream impact on trial design is substantial. Smaller, biomarker-enriched studies can deliver quicker readouts on efficacy, reducing the cost and timeline that typically burden oncology development. That matters. A lot.

But Safety Shadows Follow Old Molecules

But that framing misses something. The same drug that offers hope carries a boxed warning from the FDA in 2020 for substantial neuropsychiatric side effects like suicidal thoughts and mood changes. The label is sobering. It's for cancer patients already navigating severe physical and emotional stress. Zhang acknowledged the concern. He floated the possibility of targeting CysLTR1 with an antibody instead of the small molecule, potentially sidestepping the central nervous system toxicity. That alternative remains hypothetical, and it'd require a longer development arc, but it indicates the team isn't blindly pushing montelukast repurposing without acknowledging the real-world constraints. Shakti Ranjan Satapathy, a postdoctoral researcher at Lund University who wasn't involved in the study, called the work “important and timely” but issued a detailed caution.

“Repurposing an approved drug still requires an appropriate dose, dosing schedule, patient selection strategy, safety monitoring, pharmacodynamic readouts, and evidence of benefit in combination with immunotherapy,” he said.

His checklist hangs over every translation effort and will be the rubric by which funders evaluate the next phase of this research.

Where the Science Meets the Funding Decision

Nature Cancer published on Tuesday. But already the practical questions outrun the preclinical data. The team will try to launch a clinical trial, a step that Zhang acknowledges is sometimes difficult but may be “a little bit less challenging” because montelukast is already on pharmacy shelves. The costs of dose-finding and initial safety work are partly mitigated, although the requirements Satapathy outlined still stand. So investors and grant-making bodies reading this study will see a combination strategy that could be tested relatively quickly. They'll also see a biomarker hypothesis that, if confirmed, could carve out a strong intellectual property position around method-of-use and patient selection, and a market need that's neither niche nor saturated. Cancers in the study included triple-negative breast, colon, and melanoma-like tumours, each representing large patient groups with limited options once checkpoint inhibitors fail.

Read alongside recent announcements, the picture clarifies. The industry quietly hunts for ways to make resistant tumours responsive without turning to prohibitively expensive bespoke biologics. Montelukast repurposing fits that appetite. It's a low-cost, mechanistically clean agent that could be paired with existing immunotherapies under a companion diagnostics framework. The next two years will reveal whether the human data holds up. But for now, the science has injected a tangible hypothesis into the pipeline, and the strategic community will be watching for the first clinical signals with a mixture of caution and quiet anticipation.